Empowered Funds LLC Purchases Shares of 33,266 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Empowered Funds LLC bought a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 33,266 shares of the company's stock, valued at approximately $1,376,000. Empowered Funds LLC owned about 0.07% of Mirum Pharmaceuticals at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of MIRM. Creative Planning purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter valued at approximately $249,000. Hennion & Walsh Asset Management Inc. grew its stake in shares of Mirum Pharmaceuticals by 10.8% in the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 116,054 shares of the company's stock valued at $4,526,000 after purchasing an additional 11,284 shares during the last quarter. Values First Advisors Inc. grew its stake in shares of Mirum Pharmaceuticals by 20.1% in the 3rd quarter. Values First Advisors Inc. now owns 23,725 shares of the company's stock valued at $925,000 after purchasing an additional 3,971 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 22.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after purchasing an additional 318 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Mirum Pharmaceuticals by 65.7% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,176 shares of the company's stock valued at $358,000 after purchasing an additional 3,639 shares during the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Citigroup raised their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, Robert W. Baird raised their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an "outperform" rating in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $57.10.

Mirum Pharmaceuticals Price Performance

MIRM stock traded up $0.99 during midday trading on Thursday, hitting $53.16. 510,111 shares of the stock were exchanged, compared to its average volume of 513,222. The stock's 50-day moving average price is $45.79 and its 200-day moving average price is $42.90. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -26.32 and a beta of 0.96. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $53.76. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Insider Transactions at Mirum Pharmaceuticals

In other news, CEO Christopher Peetz sold 9,102 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the transaction, the chief executive officer now directly owns 115,920 shares of the company's stock, valued at $5,589,662.40. The trade was a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Peter Radovich sold 2,627 shares of the business's stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the transaction, the chief operating officer now directly owns 26,961 shares of the company's stock, valued at approximately $1,300,059.42. This trade represents a 8.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,915 shares of company stock valued at $1,897,920 over the last three months. 22.87% of the stock is currently owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.